SRX Global Inc.SRXH
Price (close)
$1.73
Market cap
—
P/E
—
Revenue (TTM)
$13.5M
Net income
-$34.4M
Dividend yield
2.89%
1-year total return
-91.3%
Net margin
-254.8%
Revenue growth
—
Debt / equity
0.00x
What SRX Global Inc. does.
SRx was engaged in specialty pharmaceuticals and healthcare services, including a series of acquisitions to expand its operations. These
legacy operations faced financial difficulties and subsequently filed for bankruptcy, resulting in the winding down of the majority of
Company’s continuing operations consist of the pet health and wellness business formerly operated by Better Choice. This business
Revenue and profit, by fiscal year.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $6.5M |
| Net income | — | — | — | — | -$43.1M | -$45.0M |
More on SRXH.
- SRX Global Inc. summary
- SRX Global Inc. financial statements
- SRX Global Inc. key metrics
- SRX Global Inc. health scores and style box
- SRX Global Inc. earnings
- SRX Global Inc. dividends
- SRX Global Inc. valuation
- SRX Global Inc. ownership and insiders
- SRX Global Inc. peers
Figures from SRX Global Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.